DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Untch M, Fasching PA, Konecny GE. et al.
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
J Clin Oncol 2011;
29: 3351-3357
We do not assume any responsibility for the contents of the web pages of other providers.